Blog
RSS FeedPosted by Michael Wonder on 06 Sep 2022
InnoCare announces priority review of orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma by NMPA
6 September 2022 - InnoCare Pharma announced today that BTK inhibitor orelabrutinib has been granted priority review for the treatment of ...
Posted by Michael Wonder on 06 Sep 2022
Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE
6 September 2022 - Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival. ...
Posted by Michael Wonder on 06 Sep 2022
ICR criticises NICE rejection of olaparib for advanced prostate cancer
6 September 2022 - The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not ...
Posted by Michael Wonder on 06 Sep 2022
Italian Medicines Agency approves reimbursed access to Bylvay (odevixibat) for patients with all PFIC types
6 September 2022 - Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the ...
Posted by Michael Wonder on 06 Sep 2022
Amazon eyes Japan's online prescription drug market
5 September 2022 - E-commerce giant considers creating platform with local pharmacies. ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC promises equity boost in first official response to independent review
6 September 2022 - PHARMAC will supercharge its commitment to Māori and diverse communities, which could see different medicines funded, ...
Posted by Michael Wonder on 05 Sep 2022
International work-sharing - first medicines approved by all five Access Consortium regulators
2 September 2022 - The TGA has approved two new medicines as part of the Access New Active-Substance Work-Sharing Initiative. ...
Posted by Michael Wonder on 05 Sep 2022
Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes
5 September 2022 - Approval marks the first SGLT-2 inhibitor approved in China for chronic kidney disease in adult patients ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 05 Sep 2022
Collaboration arrangement between the Department of Health and Aged Care and Health Technology Assessment bodies in the United Kingdom and Canada
5 September 2022 - The Department of Health and Aged Care has signed an international collaboration arrangement with five like minded ...
Posted by Michael Wonder on 04 Sep 2022
Australia among world's best in treating debilitating and often fatal muscle disorder
4 September - Australia has become one of the first countries in the world to fund a new, next-generation treatment ...
Posted by Michael Wonder on 02 Sep 2022
The CEO of GoodRx doesn’t think mail order pharmacies are the ‘right answer’ to lowering prescription drug prices
2 September 2022 - Cartoonishly high hospital bills, overpriced prescription drugs, crowdsourcing for medical treatments—these are all features of the US ...
Posted by Michael Wonder on 02 Sep 2022
FDA still skeptical of ALS drug ahead of high stakes meeting
3 September 2022 - The U.S. FDA has posted another negative review of a closely watched drug for the deadly neurodegenerative ...
Posted by Michael Wonder on 02 Sep 2022
Call for Keytruda: Bay of Plenty couple needs help funding hefty cancer treatment
1 September 2022 - Tim Pardy thought he'd beat it. Five months later his pancreatic cancer not only returned, but it ...
Posted by Michael Wonder on 02 Sep 2022
Bayer’s Keredia (finerenone) receives updated label to include findings from Phase 3 FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes
1 September 2022 - US label now inclusive of data from comprehensive Phase 3 clinical trial program (FIGARO-DKD and FIDELIO-DKD) investigating ...